140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
Titel:
140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
Auteur:
Ayoub, J-P. Friedlander, M.L. Dieras, V.C. Wildiers, H. Arun, B. Han, H.S. Puhalla, S. Shparyk, Y. Jakobsen, E.H. Kundu, M.G. Wu, M. Ratajczak, C. Maag, D. Kaufman, B.